Scancell’s lead ImmunoBody® cancer vaccine, SCIB1, is being developed for the treatment of patients with metastatic melanoma. SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. Both proteins play key roles in the production of melanin in the skin.


A Phase 1/2 study of SCIB1 in 35 patients with stage III or IV disease, in which 15 patients had tumours present and 20 had fully-resected disease at study entry has been successfully completed. Dose-dependent T cell responses were induced in nearly 90% of patients with no serious adverse events or dose limiting toxicities. At the data cut-off point for the main study, all 20 fully-resected patients were alive, with a median observation time of 37 months from study entry. In the 16 patients with fully-resected disease who received 2-4 mg doses of SCIB1, 14 were still alive 5 years after the study had started. The melanoma recurrence rates in resected SCIB1-treated patients were also lower than in historical controls.


Immune checkpoint inhibitors (CPIs) such as Keytruda® (pembrolizumab) and Opdivo® (nivolumab) relieve the immunosuppression present in the tumour microenvironment, which can affect an individual’s immune response to their cancer. There is a clear rationale for using an ImmunoBody® to prime an immune response against a tumour to enhance the efficacy of such CPIs. This potential has been confirmed in preclinical studies, which indicate that SCIB1 and an anti-PD1 antibody CPI have similar activity levels as monotherapies and have a strong synergistic effect when administered together. The combination of CPI treatment with a therapeutic vaccine has the potential to increase the proportion of patients who respond to the combined treatment. This hypothesis is being tested in Scancell’s Phase 2 clinical study of SCIB1 in late-stage melanoma patients receiving Keytruda® as standard of care [NCT04079166].

Further information about the trial can be found here.


The SCIB1 ImmunoBody® expresses a select number of melanoma-specific T cell epitopes that restricts its potential efficacy to approximately 40% of patients. The modified vector SCIB1+ includes the same epitopes as SCIB1 but now also includes several more epitopes to overcome this limitation. In a further modification, the Fc region of the SCIB1+ product was improved using the AvidiMab® technology, generating the iSCIB1+ DNA vector, to enhance the Fc targeting of the ImmunoBody® to dendritic cells resulting in the induction of higher frequency T cell responses.

SCOPE Clinical Advisory Board

Dr Heather Shaw, FRCP (Consultant Medical Oncologist)
Prof. James Larkin
(Consultant Medical Oncologist)
Dr Miranda Payne
(Consultant in Medical Oncology)
Prof. Poulam Patel MBBS, FRCP, PhD (Professor of Clinical Oncology)
Dr. Pippa Corrie PhD FRCP (Consultant & Associate Lecturer in Medical Oncology)